Business
Santhera Announces Half Year 2025 Financial Results and Provides Corporate Update
Ad hoc announcement pursuant to Art. 53 LR A conference call will be held on September 23, 2025, at 14:00 CEST / 13:00 BST / 08:00 EDT. Details are at the end of this news release Pratteln, Switzerland, September 23, 2025 – Santhera Pharmaceuticals (SIX: SANN) announces the Company’s financial results for the six months ended June 30, 2025, reports on progress with AGAMREE® (vamorolone) for the treatment of Duchenne muscular dystrophy (DMD) and provides updates on its corporate and financing ini
About this update from Santhera Pharmaceuticals Holding Ag
[{"type":"image","alt":"Santhera Pharmaceuticals Holding AG","displaySize":"","headline":null,"caption":"Santhera Pharmaceuticals Holding AG","className":"","disableSlideshowImg":false,"size":{"original":{"width":235,"height":71,"url":"https://media.zenfs.com/en/globenewswire.com/69b76b9d28605c9cb06e9f424ed2d9b3"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/m.yMU32TDRiiNbpVl.Y_mw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEyNztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/69b76b9d28605c9cb06e9f424ed2d9b3","width":235,"height":71}},"lazy":false},{"type":"text","content":"Ad hoc announcement pursuant to Art. 53 LR","length":42,"tagName":"p"},{"type":"text","content":"A conference call will be held on September 23, 2025, at 14:00 CEST / 13:00 BST / 08:00 EDT. Details are at the end of this news release","length":137,"tagName":"p","attribs":{}},{"type":"text","content":"Pratteln, Switzerland, September 23, 2025 – Santhera Pharmaceuticals (SIX: SANN) announces the Company’s financial results for the six months ended June 30, 2025, reports on progress with AGAMREE® (vamorolone) for the treatment of Duchenne muscular dystrophy (DMD) and provides updates on its corporate and financing initiatives.","length":329,"tagName":"p"},{"type":"text","content":"Highlights","length":10,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Total revenue increased 70% to CHF 24 million (H1 2024: CHF 14.1 million) driven by strong sales growth in launched markets in addition to growing royalty and product supply revenues","length":182,"tagName":"p"}]},{"val":[{"type":"text","content":"Product sales increased 76% to CHF 11.6 million (H1 2024: CHF 6.6 million), led by Germany and Austria with first contributions from the UK following the Q2 launch","length":163,"tagName":"p"}]},{"val":[{"type":"text","content":"Royalties from licensing partners in the U.S. and China of CHF 5.4 million (H1 2024: CHF 0.9 million), already >25% above full year 2024; further acceleration expected in H2 2025","length":181,"tagName":"p"}]},{"val":[{"type":"text","content":"Global sales (including partners) of AGAMREE exceed USD 100 million on a four consecutive quarter basis, ahead of expectations, triggering a USD 25 million sales milestone payment due, reflected in cost of sales (COS)","length":217,"tagName":"p"}]},{"val":[{"type":"text","content":"Operating expenses ...